[B cell acute lymphoblastic leukemia therapy: an up to date overview]

Area of Science:

• Hematology
• Oncology
• Pediatric Medicine

Background:

• Retrospective analysis in 2000 suggested pediatric-like therapy benefits adolescent and young adult (AYA) leukemia (ALL) patients.
• Over two decades of research have confirmed the efficacy and safety of this approach for AYA and older adult ALL.
• Pediatric ALL treatment has advanced with innovations like minimal residual disease (MRD) stratification.

Purpose of the Study:

• To review frontline studies on pediatric-like therapy for adolescent and young adult (AYA) leukemia (ALL).
• To discuss the evolving treatment landscape for adult B-cell acute lymphoblastic leukemia (B-ALL).
• To highlight the potential of newly approved anti-cancer drugs in improving outcomes.

Main Methods:

• Review of prospective studies evaluating pediatric-like therapy in AYA and adult ALL.
• Analysis of advancements in pediatric ALL treatment, including MRD stratification.
• Inclusion of data on newly approved drugs like inotuzumab ozogamicin and blinatumomab.

Main Results:

• Prospective studies consistently confirm the efficacy and safety of pediatric-like therapy for AYA and older adult ALL.
• Minimal residual disease (MRD) stratification represents a significant advancement in pediatric ALL therapy.
• Emerging anti-cancer drugs show promise for further improving treatment outcomes.

Conclusions:

• Pediatric-like therapy is a validated and effective treatment strategy for adolescent and young adult (AYA) leukemia (ALL).
• Continued progress in ALL treatment is driven by technological innovations and novel therapeutic agents.
• The integration of new drugs and MRD-guided approaches offers a promising future for adult B-ALL management.